Episode 56: Committed – The Trials and Tribulations of Psychiatry Training

Adam Stern Podcast Episode

Episode 56: Committed – The Trials and Tribulations of Psychiatry Training

Adam Stern, MD, neuropsychiatrist and assistant professor of psychiatry, Harvard Medical School, joins the show to discuss his book “Committed: Dispatches from a Psychiatrist in Training” and the struggles that psychiatry trainees face today. Dr. Stern hits on an unexpected diagnosis he was given three years ago, dealing with imposter syndrome, the cruelty of survival rates when given to individual patients, anecdotes in the book that highlight the nuances of psychiatry training, the need for human connection while practicing, advice for coming out of training successfully, and so much more in this invigorating conversation.

Related Resources

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More